Source: CNBC
“AstraZeneca on Monday said it plans to invest $50 billion in bolstering its U.S. manufacturing and research capabilities by 2030, becoming the latest pharmaceutical firm to ramp up its stateside spending in the wake of U.S. trade tariffs. The Anglo-Swedish biotech company, which is headquartered in Cambridge, England, said the ‘cornerstone’ of the commitment would be a new multi-billion dollar facility to produce its weight management and metabolic portfolio, including its oral GLP-1 obesity pill. The facility, planned for the Commonwealth of Virginia, is set to be AstraZeneca’s largest single manufacturing investment in the world and will ‘leverage AI, automation and data analytics to optimize production,’ the company said.” (07/22/25)